Breast cancer proteomics: clinical perspectives

Thomas YK Lau

‌¹^,³, Darran P O’Connor

‌¹, Donal J Brennan

‌¹, Michael J Duffy

‌², Stephen R Pennington

‌³ & William M Gallagher

‌^†⁴

¹UCD Conway Institute, UCD School of Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin 4, Ireland

²St. Vincent’s University Hospital, Dublin 4, Ireland

³UCD Conway Institute, Proteome Research Centre, University College Dublin, Dublin 4, Ireland

⁴Associate Professor of Cancer Biology, UCD Conway Institute, UCD School of Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin 4, Ireland. william.gallagher@ucd.ie

†

Author for correspondence

Breast cancer is the one of leading causes of cancer-related deaths in women within economically developed regions of the world. A major focus of present research into this malignancy is the identification of new biomarkers and drug targets to improve detection and treatment. Proteomics represents one of the latest technological developments in this context. It aims to analyse the complex circuitry of the breast cancer proteome. Here, the authors review how breast cancer proteomics has progressed so far, with emphasis on its potential application to clinically relevant scenarios.

Full Text | PDF (291 KB) | PDF Plus (444 KB)

Forward Links to Citing Articles

Serhiy Souchelnytskyi, Louise Alldridge. (2008) Breast Cancer and Proteomics: The inaugural Mammary Gland Proteome Initiative (MGPI) workshop 12–13 July 2007, Cambridge, UK. PROTEOMICS – CLINICAL APPLICATIONS 2:1, 8-10
Online publication date: 1-Feb-2008.
CrossRef